skip to Main Content

schmulsonMax J. Schmulson W., MD

Professor of Medicine
Department of Experimental Medicine
Faculty of Medicine-Universidad Nacional Autónoma
de México (UNAM)
Hospital General de México
Mexico City, Mexico


Dr. Schmulson is Professor of Medicine of the Universidad Nacional Autónoma de México (UNAM) and currently works in the Laboratory of Liver, Pancreas and Motility (HIPAM) of the Department of Experimental Medicine located in the Hospital General de México. His research is focused on the epidemiology, quality of life of FGIDs and on the immunological factors associated with IBS.

Dr. Schmulson also works in Clínica Lomas Altas in Mexico City where he runs the Motility Unit as well as in the ABC Hospital. He is a member of the National System of Researchers (SNI-CONACyT) and of the National Academy of Medicine of Mexico. He has published more than 60 papers in peer review journals, 45 chapters in books and has edited two books. He has received the award “Dr. Abraham Ayala González” in Clinical Research on five opportunities and the Epidemiological Research award from the Mexican Gastroenterological Association. In 2006 he was one of the founders of the Latin American Society for Neurogastroenterology (SLNG) and served as the first president, and serves in the External Medical Advisory Board of the IFFGD. He is currently Editor in Chief of the Revista de Gastroenterología de México and Associated Editor of the American Journal of Gastroenterology.

Dr. Schmulson worked on the Spanish translation of the Rome II Modular Questionnaire and Rome III Adult Questionnaire and served on the Management and Design of Treatment Trials Committee of the Rome CD Slide Set. He was a charter member of the Rome Foundation International Liaison Committee and served as Chair from 2009 to May 2013. He is a member of the Multinational Working Team of the Rome Foundation that recently released its report and is currently serving as member of the Multi-Cultural Aspects and Design of Treatment Trials chapters of Rome IV and in the IBS Global Study Executive Committee.

Back To Top